Nov. 7 at 3:22 PM
Oric Pharmaceuticals Inc. published a peer-reviewed research article in Cancer Research about its cancer drug enozertinib.
The clinical-stage oncology company's article details the discovery and development of enozertinib, a brain-penetrating inhibitor targeting exon 20 mutations of EGFR in non-small cell lung cancer (NSCLC). According to the publication, the drug showed "exquisite kinase selectivity, strong potency, brain penetration, and antitumor activity" in preclinical studies.
The research highlights a case where treatment with enozertinib led to a complete response of all systemic and brain metastases in a patient with NSCLC and an EGFR exon 20 insertion mutation. Oric claims this makes enozertinib the only EGFR exon 20 inhibitor to demonstrate complete responses both systemically and in the CNS in a patient with untreated brain metastases.
$ORIC